Contact
searchSearch
HMP Global
Login

Myelofibrosis News

News
Myelofibrosis Symptom Assessment Tool Demonstrates Strong Validity and Reliability in Trials
04/15/2025
Lisa Kuhns, PhD, MD
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom...
04/15/2025
Journal of Clinical Pathways
News
Health Care Burden Associated With Anemia in Ruxolitinib-Treated Myelofibrosis
04/08/2025
Juliet Gallagher
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using...
04/08/2025
Journal of Clinical Pathways
News
Oral JAK2 Inhibitor Offers a Viable Second-Line Treatment for Myelofibrosis, but Challenges Remain
03/13/2025
Lisa Kuhns, PhD, MD
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2...
03/13/2025
Journal of Clinical Pathways
News
Ruxolitinib Prior to Transplantation Linked to Better Survival in Myelofibrosis
03/05/2025
Grace Taylor, MS, MA
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of...
03/05/2025
Journal of Clinical Pathways
News
Momelotinib Offsets Transfusion-Related Burden and Costs in Myelofibrosis Treatment
02/19/2025
Grace Taylor, MS, MA
A study published in Cancer reveals that momelotinib reduces transfusion costs and time burden for patients with myelofibrosis compared to ruxolitinib and best available therapy.
A study published in Cancer reveals that momelotinib reduces transfusion costs and time burden for patients with myelofibrosis compared to ruxolitinib and best available therapy.
A study published in Cancer...
02/19/2025
Journal of Clinical Pathways
News
Study Highlights Momelotinib as a Promising Alternative for Myelofibrosis With Anemia
02/05/2025
Grace Taylor, MS, MA
A real-world study shows that momelotinib effectively improves anemia, reduces symptoms, and controls splenomegaly in patients with myelofibrosis, including those previously treated with other JAK inhibitors.
A real-world study shows that momelotinib effectively improves anemia, reduces symptoms, and controls splenomegaly in patients with myelofibrosis, including those previously treated with other JAK inhibitors.
A real-world study shows that...
02/05/2025
Journal of Clinical Pathways
News
Refining Risk Stratification for Myelofibrosis Using Real-World Data
12/20/2024
Juliet Gallagher
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in...
12/20/2024
Journal of Clinical Pathways
News
Antilymphocyte Globulin Improves Outcomes in Patients With Myelofibrosis Undergoing Stem Cell Transplantation
11/22/2024
Lisa Kuhns, PhD, MD
Using antithymocyte/antilymphocyte globulin (ATLG) in patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) may improve graft-versus-host disease-free and relapse-free survival (GRFS) rates.
Using antithymocyte/antilymphocyte globulin (ATLG) in patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) may improve graft-versus-host disease-free and relapse-free survival (GRFS) rates.
Using...
11/22/2024
Journal of Clinical Pathways
News
Thrombosis and Inflammation Drive Mortality and Cancer Risk in Myeloproliferative Disorders
11/15/2024
Lisa Kuhns, PhD, MD
Despite the advancements in treatment, thrombosis remains a significant challenge for patients with myeloproliferative neoplasms (MPNs), leading to increased mortality and the development of secondary cancers.
Despite the advancements in treatment, thrombosis remains a significant challenge for patients with myeloproliferative neoplasms (MPNs), leading to increased mortality and the development of secondary cancers.
Despite the advancements in...
11/15/2024
Journal of Clinical Pathways
News
Experts Reach Consensus on Myelofibrosis Management, Offering New Hope for Patients
11/08/2024
Lisa Kuhns, PhD, MD
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international...
11/08/2024
Journal of Clinical Pathways
JCP March/April 2025

Current Issue

April 2025
Volume 11
Issue 2
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use